JP6116847B2 - シクロデキストリンとの混合体を含有する錠剤 - Google Patents

シクロデキストリンとの混合体を含有する錠剤 Download PDF

Info

Publication number
JP6116847B2
JP6116847B2 JP2012219334A JP2012219334A JP6116847B2 JP 6116847 B2 JP6116847 B2 JP 6116847B2 JP 2012219334 A JP2012219334 A JP 2012219334A JP 2012219334 A JP2012219334 A JP 2012219334A JP 6116847 B2 JP6116847 B2 JP 6116847B2
Authority
JP
Japan
Prior art keywords
tablet
mixture
weight
amount
total amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012219334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014070061A5 (OSRAM
JP2014070061A (ja
Inventor
慎介 大場
慎介 大場
敬康 豊田
敬康 豊田
里美 池内
里美 池内
巧 原
巧 原
恵美子 村山
恵美子 村山
圭 元永
圭 元永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambit Bioscience Corp
Original Assignee
Ambit Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Bioscience Corp filed Critical Ambit Bioscience Corp
Priority to JP2012219334A priority Critical patent/JP6116847B2/ja
Priority to EP13776660.6A priority patent/EP2903593B1/en
Priority to ES13776660.6T priority patent/ES2665868T3/es
Priority to PCT/US2013/062577 priority patent/WO2014055397A1/en
Priority to US14/432,387 priority patent/US9675549B2/en
Publication of JP2014070061A publication Critical patent/JP2014070061A/ja
Publication of JP2014070061A5 publication Critical patent/JP2014070061A5/ja
Application granted granted Critical
Publication of JP6116847B2 publication Critical patent/JP6116847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012219334A 2012-10-01 2012-10-01 シクロデキストリンとの混合体を含有する錠剤 Active JP6116847B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2012219334A JP6116847B2 (ja) 2012-10-01 2012-10-01 シクロデキストリンとの混合体を含有する錠剤
EP13776660.6A EP2903593B1 (en) 2012-10-01 2013-09-30 Tablet containing composite with cyclodextrin
ES13776660.6T ES2665868T3 (es) 2012-10-01 2013-09-30 Comprimido que contiene material compuesto con ciclodextrina
PCT/US2013/062577 WO2014055397A1 (en) 2012-10-01 2013-09-30 Tablet containing composite with cyclodextrin
US14/432,387 US9675549B2 (en) 2012-10-01 2013-09-30 Tablet containing composite with cyclodextrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012219334A JP6116847B2 (ja) 2012-10-01 2012-10-01 シクロデキストリンとの混合体を含有する錠剤

Publications (3)

Publication Number Publication Date
JP2014070061A JP2014070061A (ja) 2014-04-21
JP2014070061A5 JP2014070061A5 (OSRAM) 2015-11-19
JP6116847B2 true JP6116847B2 (ja) 2017-04-19

Family

ID=49354944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012219334A Active JP6116847B2 (ja) 2012-10-01 2012-10-01 シクロデキストリンとの混合体を含有する錠剤

Country Status (5)

Country Link
US (1) US9675549B2 (OSRAM)
EP (1) EP2903593B1 (OSRAM)
JP (1) JP6116847B2 (OSRAM)
ES (1) ES2665868T3 (OSRAM)
WO (1) WO2014055397A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
EP3260119B1 (en) 2015-02-20 2023-11-15 Daiichi Sankyo Company, Limited Combination method for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60161925A (ja) * 1984-02-02 1985-08-23 Sanwa Kagaku Kenkyusho:Kk 安定なカリジノゲナーゼ打錠製剤の製法
JP3415835B2 (ja) * 2000-06-30 2003-06-09 山之内製薬株式会社 口腔内速崩壊錠およびその製造法
JP5027375B2 (ja) * 2002-02-20 2012-09-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 改良製剤
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
JP2005314413A (ja) * 2004-04-02 2005-11-10 Ono Pharmaceut Co Ltd 経口投与用医薬組成物
WO2007109120A2 (en) * 2006-03-17 2007-09-27 Ambit Biosciences Corporation Imidazolothiazole compounds for the treatment of disease
ES2573292T3 (es) * 2007-09-19 2016-06-07 Ambit Biosciences Corporation Formas sólidas que comprenden N-(5-terc-butil-isoxazol-3-il)-N'-{4-[7-(2-morfolin-4-il-etoxi)imidazo[2,1-b][1,3]benzotiazol-2-il]fenil}urea, composiciones de las mismas y usos de las mismas
EP2205244B1 (en) * 2007-11-08 2013-08-21 Ambit Biosciences Corporation Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy-)imidazo-[2,1-b]-[1,3]-benzothiazol-2-yl]-phenyl}urea to treat proliferative disease
JP5686736B2 (ja) * 2008-11-06 2015-03-18 アムビト ビオスシエンセス コルポラチオン プロテインキナーゼモジュレーターとしてのイミダゾロチアゾール化合物
AU2010228982B2 (en) * 2009-03-23 2015-05-14 Ambit Biosciences Corporation Methods of treatment using combination therapy
SMT202000092T1 (it) * 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220

Also Published As

Publication number Publication date
US20150250720A1 (en) 2015-09-10
WO2014055397A1 (en) 2014-04-10
ES2665868T3 (es) 2018-04-30
EP2903593A1 (en) 2015-08-12
US9675549B2 (en) 2017-06-13
JP2014070061A (ja) 2014-04-21
EP2903593B1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
KR101840182B1 (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
JP5296456B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP5714562B2 (ja) 経口用徐放性固形製剤
JP2005516946A (ja) ５ｈｔ４部分アゴニスト医薬組成物
JP6680297B2 (ja) 経口投与用医薬組成物
TWI418370B (zh) 溶出安定性製劑
US9675549B2 (en) Tablet containing composite with cyclodextrin
EP4424303A1 (en) Lenvatinib composition with improved bioavailability
JP2017141299A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2023238929A1 (ja) ピミテスピブを含有する医薬組成物
JP2015110663A (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP5900702B2 (ja) 経口投与用医薬組成物
EP3845230B1 (en) Pharmaceutical composition for oral administration
JP2022113667A (ja) エドキサバン含有医薬組成物
US20190282569A1 (en) Stable pharmaceutical composition
JP2006510665A (ja) 新規な経口即時放出型投与剤形
HK1232144A1 (zh) 经口给药用医药组合物
JP6151413B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
KR102852448B1 (ko) 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 경구투여용 제제
JP7608444B2 (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤
JP5714652B2 (ja) 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
US20250248977A1 (en) Tablet Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof
WO2025166343A1 (en) Tablet formulation of tafamidis or pharmaceutically acceptable salt thereof
WO2007049626A1 (ja) カベルゴリン含有経口固形製剤
KR20190120096A (ko) 붕해가 개선된 레날리도마이드의 경구용 정제 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170322

R150 Certificate of patent or registration of utility model

Ref document number: 6116847

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250